ReviewChildren (Basel, Switzerland)2026
Serum Cystatin C as an Early Predictive Biomarker for Acute Kidney Injury (AKI) in Neonates: A PRISMA-DTA Systematic Review.
Review in Children (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAcute kidney injury (AKI) affects 12-40% of critically ill newborns and significantly increases mortality risk. Diagnosis currently relies on serum creatinine (sCr), which rises only after substantial renal damage, so early biomarkers are needed in this vulnerable population. Serum cystatin C (sCysC) is a candidate because it is produced at a constant rate by all nucleated cells.
aimThe study aimed to investigate the diagnostic performance of sCysC for early detection of neonatal AKI.
methodsThis systematic review followed the PRISMA-DTA guidelines and is registered with PROSPERO (CRD420261302574). We searched four databases for studies measuring sCysC in neonates (0-28 days) with validated assays and creatinine-based AKI definitions as the reference standard. Studies were categorized by sampling timing as concurrent diagnostic or early predictive, and appraised with QUADAS-2 and QUIPS, respectively.
resultsThirteen studies were included. In the early predictive group, sCysC was elevated at scheduled timepoints preceding creatinine-defined AKI, with AUC values of 0.670-1.000. The concurrent diagnostic studies reported sensitivities of 84.8-88.5%, specificities of 61.8-75.0%, and AUC values of 0.844-0.849. Reported cut-offs ranged from 0.60 to 2.87 mg/L, with one sepsis-associated AKI study reporting 9.4 mg/L.
conclusionssCysC is a promising adjunctive biomarker whose earlier elevation may support earlier recognition of neonatal AKI. Standardized assays and validated population-specific thresholds are required before routine clinical use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.